Objective: To ascertain whether the molecular characterization of a defect in the low-density lipoprotein (LDL) receptor gene (LDLR) in children with heterozygous familial hypercholesterolemia (heFH) identifies subjects at greater risk of developing premature coronary artery disease (pCAD) later in life.
Study Design: We investigated 264 children with heFH from 201 families, along with 148 affected parents and 100 unaffected siblings. The lipid profile was assessed before any treatment was provided, and genotype analysis was performed to characterize LDLR defects. In a subgroup of children with heFH and controls, we measured aorta and carotid intima-media thickness (aIMT and cIMT). The prevalence of pCAD in parents and/or grandparents with heFH was recorded.
Results: The children with heFH with a family history of pCAD had higher LDL cholesterol and apolipoprotein B levels and greater aIMT and cIMT than those with negative family history. Compared with carriers of LDLR-defective mutations, carriers of LDLR-negative mutations had a more severe phenotype, in terms of plasma lipid levels and IMT, and a higher prevalence of pCAD in first-degree relatives (36% vs 6.7%; P < .001).
Conclusions: The study of heFH in children, in which other risk factors for CAD play a minor role, allows early identification of those at increased risk for developing pCAD, who merit more stringent clinical control and early pharmacologic treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jpeds.2009.02.022 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Familial hypercholesterolemia in Chinese children and adolescents: a multicenter study.
Lipids Health Dis
December 2024
Department of Endocrinology, Children's Hospital of Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, Zhejiang, 310052, China.
Background: Familial hypercholesterolemia (FH) is an inherited disorder mainly marked by increased low-density lipoprotein cholesterol (LDL-C) concentrations and a heightened risk of early-onset arteriosclerotic cardiovascular disease (ASCVD). This study seeks to characterize the genetic spectrum and genotype‒phenotype correlations of FH in Chinese pediatric individuals.
Methods: Data were gathered from individuals diagnosed with FH either clinically or genetically at multiple hospitals across mainland China from January 2016 to June 2024.
Determination of selected oxysterol levels, oxidative stress, and macrophage activation indicators in children and adolescents with familial hypercholesterolemia.
Lipids Health Dis
November 2024
Department of Medical Biochemistry, Faculty of Medicine, Tınaztepe University, Buca, Izmir, Turkey.
Aim: Elevated levels of cholesterol in the bloodstream, also referred to as hypercholesterolemia, pose a significant risk for the onset of cardiovascular and cerebrovascular diseases. Oxysterols, cholesterol-derived oxidized compounds that form enzymatically or non-enzymatically, contribute to the development of atherosclerosis and coronary artery disease. This study aimed to examine the critical oxysterol levels in children and adolescents with hypercholesterolemia and explore the correlation between these levels, oxidative stress, and atherosclerosis progression.
View Article and Find Full Text PDFEvolocumab treatment reduces carotid intima-media thickness in paediatric patients with heterozygous familial hypercholesterolaemia.
Eur J Prev Cardiol
November 2024
Clinical Lipidology and Rare Lipid Disorders Unit, Community Genomic Medicine Centre and ECOGENE-21, Department of Medicine, Université de Montréal, Chicoutimi, Quebec, Canada.
Aim: Children with heterozygous familial hypercholesterolaemia (HeFH) show greater carotid intima-media thickness (cIMT). Evolocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor monoclonal antibody, substantially reduced low-density lipoprotein cholesterol (LDL-C) and modestly reduced lipoprotein(a) in children with HeFH. We investigated evolocumab's effect on cIMT progression.
View Article and Find Full Text PDFA contemporary snapshot of familial hypercholesterolemia registries.
Curr Opin Lipidol
December 2024
Medical School, University of Western Australia, Perth.
Article Synopsis
- - Familial hypercholesterolemia (FH) registries collect important data on the management of FH, including real-world practices, epidemiology, and how late diagnoses affect cardiovascular health and healthcare use.
- - Most adult patients with heterozygous FH (HeFH) are diagnosed late and often do not achieve recommended cholesterol levels, while genetic testing is crucial for early detection in children and adolescents.
- - Data from these registries highlight the need for better strategies to improve FH care globally, particularly addressing disparities in treatment and outcomes based on income levels.
Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial Hypercholesterolemia: A Systematic Review and Meta-Analysis.
Medicina (Kaunas)
October 2024
Department of Pediatrics, West China Second Hospital, Sichuan University, Chengdu 610041, China.
Article Synopsis
- PCSK9 inhibitors, evolocumab and alirocumab, show promise in treating familial hypercholesterolemia (FH) in pediatric patients through a systematic review and meta-analysis.
- The analysis included 14 articles and found that these drugs significantly reduced low-density lipoprotein cholesterol (LDL-C) and other lipid markers, particularly in patients with heterozygous FH.
- Overall, the medications were well tolerated in children, highlighting their potential for safe use in managing lipid levels compared to prior studies in adults.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!